Phase II clinical trials of Oxford COVID-19 vaccine begin in Chennai & Pune

▴ Phase II clinical trials of Oxford COVID-19 vaccine begin in Chennai & Pune
After, Covishield's first shot, tests related to COVID-19 and antibodies came negative, officials said

Second Phase clinical trials of Oxford COVID-19 vaccine begin in Chennai and Pune. In Chennai, two prominent medical institutions are starting the second and third phase field trial of the Oxford vaccine candidate Covishield.

In another development, the Tamil Nadu Government has exempted college students having arrears except in the last semester from writing the examinations, in view of Covid-19. Previously the exemption has been made for the regular students.

Meanwhile, the total number of COVID-19 infections in the state is nearing the four lakh mark. 5958 people were tested positive yesterday taking the total to over 3,97000. However, the active caseload in the state is about 52 thousand.

Chennai is one of the seventeen locations in India to conduct the field trial of the promising vaccine candidate Covishield, developed jointly by the Oxford University and AstraZeneca. The Government Rajiv Gandhi General Hospital and the Sri Ramachandra Institute of Higher Education and Research are the two institutions in the city that run the trial.

The state director of public health Dr TS Selva Vinayagam, who coordinates the study in Chennai, told , healthy volunteers above the age of 18 are being involved in its multi-centric clinical trial. Dr TS Selva Vinayagam, Director, Public Health said, “We will be starting the Phase-2 and Phase-3 together. We will be following the volunteers for up to 180 days. This is to assess the safety, immunogenicity and reacto-genecity. We will be doing that.” The T-cells in the white blood corpuscles against the viral pathogen are said to be observed in 14-days after administering the vaccine and the antibodies in about 28 days. Their effectiveness to eliminate the virus and several other factors will be exhaustively tested during the trial.In Maharashtra, the Phase II clinical trial of the Oxford COVID-19 vaccine, being manufactured by the Serum Institute of India (SII), began at a medical college and hospital in Pune today. According to the Hospital officials, two male volunteers were administered the vaccine at Bharati Vidyapeeth's Medical College and Hospital post noon today.

Our correspondent reports, doctors at Bharati Vidyapeeth's Medical College and Hospital administered the first shot of the 'Covishield' vaccine to a 32-year-old man after his reports of COVID-19 and antibodies tests came out negative. Another 48-year-old male volunteer was also given the vaccine. According to details by the Medical Director of Bharati Vidyapeeth's Medical College Hospital and Research Centre, Dr Sanjay Lalwani, the COVID-19 and antibodies tests were conducted on the five volunteers.

Of them, the reports of three volunteers' antibodies test came out positive so they became ineligible for today's trial. The doctor informed that in all, 25 candidates will be given the vaccine in next seven days. Meanwhile, the Sangli district administration has initiated stringent action on the private hospitals which are asking to deposit advanced amount before admitting Covid positive patients. The Sangli district collector, Dr. Abhijit Choudhari said that the private hospitals cannot ask a patient to deposit advanced amount before his admission to the hospital.

Tags : #Covishield #OxfordVaccine #SerumInstitute #Pune #Chennai #Phase2trialCovidvaccine #OxfordVaccinePhase2Trial #CovishieldPhase2Trial #Astrazeneca #LatestCovidNewsAug27

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Moscow Center for Diagnostics and Telemedicine Receives License for Radiology Residency ProgramApril 02, 2025
CARE Hospitals Launches AI-Powered Non-Invasive Therapy – An innovative modality introduced in Telangana & Andhra PradeshApril 02, 2025
High-Rise Heart Attacks: Are Skyscrapers Turning Survival into a Race Against Time?April 02, 2025
DCDC’s $150 Crore Expansion: Can Innovative Clinics End India's Kidney Crisis?April 02, 2025
Medanta Rolls Out ‘Colon Tunnel on Wheels’ to Drive Awareness on Colorectal Cancer Prevention & Early DetectionApril 01, 2025
Zigly launches 2 pet hospitals, opens 4 new stores; expects ARR to more than double in 1-2 yearsApril 01, 2025
University of Leeds Announces International Masters Regional Scholarships for 2025April 01, 2025
Avantor Recognized with Two Prestigious Awards at Asia-Pacific Biopharma Excellence Awards 2025April 01, 2025
Foundation Stone Laid for Madhav Netralaya Eye Hospital & Research CentreApril 01, 2025
Doomscrolling at Midnight: How Indians Are Sacrificing Sleep for ScreensMarch 31, 2025
Essential Medicines Price Surge: Are Patients Paying the Price?March 31, 2025
Prioritize your health during the holy days of RamzanMarch 31, 2025
Tired of Stomach Cramps? These Simple Foods Can Heal Your GutMarch 31, 2025
Regional growth booming for startups in 2024 - QBO Innovation studyMarch 31, 2025
Is long-acting HIV treatment as good as taking daily pills?March 31, 2025
Right to safe abortion cannot be dislocated from human rightsMarch 28, 2025
Popeyes® Opens Third Store in Hyderabad at Inorbit MallMarch 28, 2025
Popeyes® Opens Third Store in Hyderabad at Inorbit MallMarch 28, 2025
10 New HIV Cases in 2 Months: Has Kerala’s Drug Problem Gone Too Far?March 28, 2025
Type 2 Diabetes Under Attack: The Unexpected Power of Wearable TechMarch 28, 2025